



## Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 2, 2022

WALTHAM, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the "Company" or "Viridian"), a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by current therapies, today announced that a majority of the independent directors serving on the Compensation Committee of the Company's Board of Directors approved the grant of stock options to purchase an aggregate of 103,000 shares of the Company's common stock to three new employees (the "Inducement Grants") on September 1, 2022 (the "Grant Date"). The Inducement Grants have been granted outside of the Company's Amended and Restated 2016 Equity Incentive Plan (the "Plan") but remain subject to the terms and conditions of such Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Grants have an exercise price per share that is equal to the closing price of Viridian's common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee's start date, and thereafter the remainder of the shares vest in 36 equal monthly installments, subject to continued employment through the applicable vesting dates.

### About Viridian Therapeutics

[Viridian Therapeutics](#) is a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies. Viridian's most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED). VRDN-002 is a distinct anti-IGF-1R antibody and incorporates half-life extension technology. VRDN-003 is an extended half-life version of VRDN-001. Both VRDN-002 and VRDN-003 are designed for administration as convenient, low-volume, subcutaneous injections. TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Viridian is based in Waltham, Massachusetts.

### Investor and Media Contact

John Jordan  
Viridian Therapeutics  
Vice President, Investor Relations  
& Corporate Communications  
617-272-4691  
[IR@viridiantherapeutics.com](mailto:IR@viridiantherapeutics.com)



Source: Viridian Therapeutics, Inc